Failure of Somatostatin to Affect Human Chorionic Somatomammotropin and Human Chorionic Gonadotropin Secretionin Vitro*
- 1 November 1978
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 47 (5) , 1141-1143
- https://doi.org/10.1210/jcem-47-5-1141
Abstract
The effect of somatostatin (SRIF) on human chorionic somatomammotropin (hCS) secretion was studied in human placental explants cultured in vitro. In the experimental flasks, SRIF was added in a concentration of 10, 100, and 1000 ng/ml media; hCS levels measured by RIA were not different from those found in the control flasks. In separate experiments, we investigated the action of SRIF on hCG secretion by a human malignant choriocarcinoma cell line maintained in tissue culture. SRIF (1000 ng/ml) did not inhibit basal or dibutyryl cAMP-induced stimulation of hCG secretion. These results suggest that somatostatin does not suppress hCS or hCG release in vitro from normal or malignant trophoblast, respectively.Keywords
This publication has 4 references indexed in Scilit:
- In VitroEffect of Dopamine and Pimozide on Human Chorionic Somatomammotropin (hCS) Secretion*Journal of Clinical Endocrinology & Metabolism, 1978
- Studies on Human Chorionic Gonadotropin Secretion: Effects of EGTA, Lanthanum, and the Ionophore A23187Journal of Clinical Endocrinology & Metabolism, 1977
- ACTIONS OF GROWTH HORMONE-RELEASE INHIBITING HORMONE (SOMATOSTATIN) ON THE RENIN ALDOSTERONE SYSTEMJournal of Clinical Endocrinology & Metabolism, 1976
- Somatostatin Does Not Suppress Plasma Parathyroid HormoneJournal of Clinical Endocrinology & Metabolism, 1976